An inhibitor of the bcr-abl tyrosine kinase. It acts by binding to the ATP binding site of bcr-abl. Imatinib also stimulates the entry of the bcr-abl tyrosine kinase into the nucleus, where it cannot perform its anti-apoptopic functions. It inhibits EOL-1 cell viability (IC50 = 0.5 nM), phosphorylation of a fusion protein (IC50 = 30 nM), and viability of BaF3 cells expressing Rhe-PDGFRα in the absence of IL-3 (IC50 = 0.17 nM).
PRODUCT PROPERTIES |
Formula: | | C29H31N7O . CH4SO3 |
MW: | | 589.71 |
CAS: | | 220127-57-1 |
Purity: | | ≥99% by HPLC |
Appearance: | | White to off-white solid |
Solubility: | | DMSO (100 mg/ml) |
Long Term Storage: | | -20°C |
Background / Technical Information: | | For the Original Manufacturer's data sheet please click here. |
|
|
|